Literature DB >> 3529525

Cure of murine thalassemia by bone marrow transplantation without eradication of endogenous stem cells.

G Wagemaker, T P Visser, D W van Bekkum.   

Abstract

alpha-Thalassemic heterozygous (Hbath/+) mice were used to investigate the possible selective advantage of transplanted normal (+/+) hemopoietic cells. Without conditioning by total-body irradiation (TBI), infusion of large numbers of normal bone marrow cells failed to correct the thalassemic peripheral blood phenotype. Since the recipients' stem cells are normal with respect to number and differentiation capacity, it was thought that the transplanted stem cells were not able to lodge, or that they were not stimulated to proliferate. Therefore, a nonlethal dose of TBI was given to temporarily reduce endogenous stem cell numbers and hemopoiesis. TBI doses of 2 or 3 Gy followed by infusion of normal bone marrow cells proved to be effective in replacing the thalassemic red cells by normal red cells, whereas a dose of 1 Gy was ineffective. It is concluded that cure of thalassemia by bone marrow transplantation does not necessarily require eradication of thalassemic stem cells. Consequently, the objectives of conditioning regimens for bone marrow transplantation of thalassemic patients (and possibly other nonmalignant hemopoietic disorders) should be reconsidered.

Entities:  

Mesh:

Year:  1986        PMID: 3529525     DOI: 10.1097/00007890-198609000-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

Review 1.  Somatic gene therapy for genetic disease.

Authors:  C Kinnon; R J Levinsky
Journal:  Arch Dis Child       Date:  1990-01       Impact factor: 3.791

2.  Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.

Authors:  Marshall W Huston; Adriaan R A Riegman; Rana Yadak; Yvette van Helsdingen; Helen de Boer; Niek P van Til; Gerard Wagemaker
Journal:  Hum Gene Ther       Date:  2014-10       Impact factor: 5.695

3.  Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.

Authors:  Marshall W Huston; Niek P van Til; Trudi P Visser; Shazia Arshad; Martijn H Brugman; Claudia Cattoglio; Ali Nowrouzi; Yuedan Li; Axel Schambach; Manfred Schmidt; Christopher Baum; Christof von Kalle; Fulvio Mavilio; Fang Zhang; Mike P Blundell; Adrian J Thrasher; Monique M A Verstegen; Gerard Wagemaker
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.